Photosensitizer-grafted ROS (reactive oxygen species) response type small-size zwitterionic micelle drug delivery system as well as preparation method and application thereof
By designing the ROS-responsive small-size zwitterion micelle delivery system for grafted photosensitizers, the problems of low photosensitizer delivery efficiency and poor tumor retention ability in photodynamic therapy are solved, and efficient oxygen supply and photosensitive in tumor tissues are achieved The accumulation of agents significantly improves the therapeutic effect of PDT and reduces the toxic side effects on normal tissues.
Patent Information
- Application Number
- CN202411198257.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-29
- Publication Date
- 2024-12-03
AI Technical Summary
The existing photodynamic therapy (PDT) has low photosensitive agent delivery efficiency and poor tumor retention capacity in tumor tissues, resulting in insufficient oxygen supply, limiting the therapeutic effect, and the nanocarriers become larger and lose their structure under acid/enzyme/redox conditions. Retention ability, difficult to respond effectively to stimuli.
A ROS-responsive small-size zwitterion micelle delivery system with grafted photosensitizer was designed, and the esterification reaction between photosensitizer and acrylate functional hyperbranched polycarbonate was carried out, combining thiolated zwitterionic carboxylate betaine and Dimercapto compounds, self-assembled and cross-linked to form ROS-responsive zwitterionic micelles, loading anti-angiogenic drugs to achieve long-term tumor retention and efficient treatment.
During the window period of vascular normalization, this system improves tumor vascular perfusion capacity and oxygen supply, ensures that photosensitizers produce high concentrations of ROS under laser irradiation, effectively kills tumor cells, realizes the combined treatment of vascular normalization and PDT, and has High tumor tissue selectivity reduces toxic side effects on normal tissues.
Smart Images

Figure CN119055792A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a zwitterionic micelle drug delivery system, in particular to a ROS-responsive small-size zwitterionic micelle drug delivery system grafted with a photosensitizer, and also to a preparation method and application of the zwitterionic micelle drug delivery system. Background Art
[0002] Photodynamic therapy (PDT) is a treatment for a variety of diseases. It has the advantages of minimally invasive, high spatiotemporal controllability, and good safety. In recent years, it has received increasing attention in the field of cancer treatment. During the PDT process, photosensitizers convert oxygen (O2) into reactive oxygen species (ROS) under laser irradiation to kill cancer cells. However, the abnormal tumor vasculature in tumor tissue lacks a complete vascular structure and loses its oxygen supply capacity, resulting in severe hypoxia in the tumor tissue, which limits the anti-tumor therapeutic effect of PDT. Remodeling the abnormal tumor vasculature is expected to improve the tumor treatment effect of PDT.
[0003] Clinical studies have shown that low doses of anti-angiogenic drugs can temporarily restore vascular integrity and function by pruning immature blood vessels and recruiting pericytes. This stage is called the vascular normalization window, which generally occurs after 3-5 treatments. During this period, the perfusion capacity of tumor blood vessels is improved, which can effectively alleviate hypoxia at the tumor site. The small molecule photosensitizers currently used in clinical practice have the problems of low tumor delivery efficiency and poor tumor retention capacity. After multiple administrations, there is still a problem of insufficient photosensitizer concentration in tumor tissue. ROS production depends on photosensitizer concentration and oxygen supply, both of which jointly determine the effectiveness of PDT treatment.
[0004] Nanocarriers can be loaded with a variety of drugs, prolong the blood circulation time of drugs, and increase the enrichment and retention effects at the tumor site through the rational design of carrier materials, providing a good means for the efficient synergistic treatment of tumors. The common tumor long-retention strategy at this stage utilizes the structural fracture of nanocarriers under the stimulation of acid / enzyme / redox conditions in the tumor microenvironment, which causes the carrier to deform, aggregate, and increase in size so that it can be effectively retained in the tumor tissue. This also leads to complex carrier design, and tumor specificity causes different stimulation levels in different tumors, which may cause the nanocarrier to be unable to effectively respond to stimulation and lose its long-retention ability. Therefore, drugs that have the characteristics of long-term retention at the tumor site and can achieve efficient therapeutic effects are urgently needed to be developed. Summary of the invention
[0005] Purpose of the invention: The purpose of the present invention is to provide a ROS-responsive small-size zwitterionic micelle drug delivery system grafted with a photosensitizer, and also relates to a method for preparing the above-mentioned zwitterionic micelle drug delivery system and its application in vascular normalization and photodynamic combined therapy.
[0006] Technical solution: The ROS-responsive small-size zwitterionic micelle drug delivery system of the grafted photosensitizer of the present invention is a system in which a photosensitizer and an acrylate-functional hyperbranched polycarbonate undergo an esterification reaction to obtain a hyperbranched polycarbonate grafted with a photosensitizer, and then the hyperbranched polycarbonate is reacted with a thiolated zwitterionic carboxylic acid betaine and a dithiol compound in sequence through Michael addition to obtain a thiolated zwitterionic hyperbranched polycarbonate grafted with a photosensitizer; the thiolated zwitterionic hyperbranched polycarbonate grafted with a photosensitizer and a ROS-responsive hyperbranched zwitterionic polycarbonate are self-assembled and cross-linked in an aqueous solution to obtain ROS-responsive zwitterionic micelles grafted with a photosensitizer, and the micelles are loaded with anti-angiogenic drugs.
[0007] The structure of the acrylate functional hyperbranched polycarbonate is shown in the general formula (I), and the structure of the ROS responsive hyperbranched zwitterionic polycarbonate is shown in the general formula (II), wherein R1 is selected from H or CH3, and R2 is selected from C2-C4 alkyl or C4-C8 aromatic:
[0008]
[0009] Wherein, the photosensitizer is a compound with a carboxyl functional group, preferably Ce6, protoporphyrin IX, hematoporphyrin, benzochloroporphyrin and pheophorbide A; the anti-angiogenic drug is a tyrosine kinase inhibitor of the tinib class; and the disulfide compound is selected from the compounds shown in the following structure: Among them, n=1-50.
[0010] Wherein, in the drug delivery system, the size of the carrier is 5-20nm.
[0011] The method for preparing the zwitterionic micelle drug delivery system comprises the following steps:
[0012] (1) esterifying a photosensitizer and an acrylate functional hyperbranched polycarbonate to obtain a hyperbranched polycarbonate grafted with a photosensitizer, and then sequentially reacting the photosensitizer with a thiolated zwitterionic carboxylic acid betaine and a dithiol compound through Michael addition to obtain a thiolated zwitterionic hyperbranched polycarbonate grafted with a photosensitizer;
[0013] (2) self-assembling the thiolated zwitterionic hyperbranched polycarbonate grafted with the photosensitizer and the ROS-responsive hyperbranched zwitterionic polycarbonate in an aqueous solution, adding a catalyst triethylamine, and stirring to crosslink to obtain ROS-responsive zwitterionic micelles grafted with the photosensitizer;
[0014] (3) Loading the ROS-responsive zwitterionic micelles grafted with photosensitizer with anti-angiogenic drugs to obtain the ROS-responsive zwitterionic micelle drug delivery system grafted with photosensitizer.
[0015] Wherein, in step (1), the reaction formula for the synthesis of the thiol-modified zwitterionic hyperbranched polycarbonate grafted with a photosensitizer is:
[0016]
[0017] Wherein, in step (1), the molar ratio of the photosensitizer, the acrylate functional hyperbranched polycarbonate, the thiolated zwitterionic carboxylic acid betaine and the dithiol compound is 0.1:1:0.4-0.6:0.1-0.2.
[0018] Wherein, in step (2), the molar ratio of the thiol-modified zwitterionic hyperbranched polycarbonate grafted with the photosensitizer to the ROS-responsive hyperbranched zwitterionic polycarbonate is 1:1.
[0019] Wherein, in step (3), the mass ratio of the ROS-responsive zwitterionic micelles grafted with the photosensitizer to the anti-angiogenic drug is 1:0.1-0.2.
[0020] The ROS-responsive zwitterionic micelle drug delivery system grafted with photosensitizer can also be used in the preparation of drugs for vascular normalization and photodynamic combined therapy.
[0021] Wherein, the tumor retention time of the zwitterionic micelle drug delivery system is greater than 5 days.
[0022] Principle of the invention: The present invention constructs a nanocarrier with long tumor retention capacity to carry anti-vascular drugs and photosensitizers, overcoming the problem that the hypoxic microenvironment of tumor tissue and insufficient photosensitizer concentration seriously limit the therapeutic effect of PDT, normalizing blood vessels and improving the perfusion capacity of tumor blood vessels, effectively alleviating hypoxia in the tumor site; while performing multiple vascular normalization treatments in the early stage, the photosensitizer can be effectively accumulated in the tumor site. During the vascular normalization window period, sufficient oxygen supply and a large amount of accumulated photosensitizers produce high concentrations of ROS under laser irradiation to effectively kill tumors, giving full play to the combined treatment advantages of vascular normalization and PDT, and achieving a synergistic therapeutic effect.
[0023] Specifically, the thiol-modified zwitterionic hyperbranched polycarbonate grafted with photosensitizer and the ROS-responsive hyperbranched zwitterionic polycarbonate are self-assembled in an aqueous solution, the catalyst triethylamine is added, and the ROS-responsive zwitterionic micelles grafted with the photosensitizer are obtained by stirring and cross-linking; and the DMSO solution of the anti-vascular drug tyrosine kinase inhibitor is added under ultrasound to obtain ROS-responsive zwitterionic micelles for delivering anti-vascular drugs and photosensitizers for vascular normalization and photodynamic combined therapy.
[0024] ROS-responsive zwitterionic micelles for delivering antivascular drugs and photosensitizers can improve drug stability, prolong blood circulation time, release drugs at specific locations in tumor tissues, and effectively deliver multiple drugs to tumor tissues, providing an effective means for tumor vascular normalization and combined photodynamic therapy. ROS-responsive zwitterionic micelles for delivering antivascular drugs and photosensitizers respond to ROS stimulation near tumor blood vessels to release antivascular drug tyrosine kinase inhibitors for pruning blood vessels to achieve vascular normalization, improve the perfusion capacity of tumor blood vessels, increase oxygen supply, and effectively alleviate hypoxia in the tumor site. Furthermore, the advantages of zwitterionic tumor enrichment and retention combined with the characteristics of the small size of the carrier exert a synergistic effect to further extend the tumor retention time of the zwitterionic micelles grafted with photosensitizers (>5 days), playing the role of a photosensitizer "reservoir", which effectively improves the utilization efficiency of the carrier and makes full use of the opportunity of previous vascular normalization therapy to achieve a large accumulation of photosensitizers in tumor tissues. When the vascular normalization window arrives, sufficient oxygen supply and high concentration of photosensitizer produce a large amount of ROS under laser irradiation to effectively kill tumors, giving full play to the combined therapeutic advantages of vascular normalization and PDT.
[0025] Beneficial effects: Compared with the prior art, the present invention has the following significant advantages: (1) The zwitterionic micelle drug delivery system of the present invention has the characteristics of long-term retention in the tumor site while performing vascular normalization treatment, so that the photosensitizer can be effectively accumulated in the tumor tissue. When the tumor normalization window period is reached after multiple treatments, the tumor hypoxia is significantly improved. At the same time, the large amount of accumulated photosensitizer produces high-concentration ROS under laser irradiation to kill tumor cells, effectively realizing the combined treatment of vascular normalization and photodynamic therapy; (2) The zwitterionic micelle drug delivery system of the present invention shows high tumor tissue selectivity, and the photosensitizer is less distributed in normal tissues / organs, which effectively reduces the toxic and side effects of photodynamic therapy; (3) The preparation method of the zwitterionic micelle drug delivery system of the present invention is simple and convenient, and the reaction conditions are mild, which is suitable for large-scale production. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] Figure 1 1 is a high performance liquid chromatogram of the thiolated zwitterionic hyperbranched polycarbonate (hPCCB-Ce6-SH) grafted with photosensitizer Ce6 in Example 1;
[0027] Figure 2 This is a particle size diagram of the ROS-responsive zwitterionic micelles grafted with photosensitizer Ce6 in Example 2;
[0028] Figure 3 This is the UV-visible absorption spectrum of the ROS-responsive zwitterionic micelle grafted with photosensitizer Ce6 in Example 2;
[0029] Figure 4is the singlet oxygen generation capacity of the ROS-responsive zwitterionic micelles grafted with photosensitizer Ce6 in Example 3, wherein A is the change of SOSG fluorescence over time, and B is the statistics of SOSG fluorescence under different light intensities;
[0030] Figure 5 is the cell survival rate of the ROS-responsive zwitterionic micelles grafted with photosensitizer Ce6 under different conditions in Example 4;
[0031] Figure 6 The photoacoustic imaging results of the tumor in Example 5, wherein A is the blood oxygen imaging image of the tumor tissue, and B is the quantitative statistics of the oxygen-containing tumor tissue;
[0032] Figure 7 The expression level of HIF-1α in tumor tissue in Example 5, wherein A is the immunofluorescence image of HIF-1α, and B is the statistics of the positive ratio of HIF-1α;
[0033] Figure 8 The enrichment and retention of ROS-responsive zwitterionic micelles in the tumor in Example 6, wherein A is the in vivo fluorescence imaging result and B is the in vitro fluorescence imaging result;
[0034] Fig. 9 These are the results of the combined treatment of tumor vascular normalization and photodynamic therapy on 4T1 tumor-bearing mice in Example 7, wherein A is the in vitro tumor result, B is the tumor weight analysis, and C is the ROS fluorescence signal in the tumor tissue. DETAILED DESCRIPTION
[0035] The technical scheme of the present invention is further described below in conjunction with the examples. The test materials used in the examples can all be purchased through conventional channels.
[0036] Example 1
[0037] Thiol-modified zwitterionic hyperbranched polycarbonate hPC grafted with photosensitizer Ce6 CB Synthesis of Ce6-SH:
[0038] Hyperbranched polycarbonate hPC-AC (1.0 g, 1.34 mmol of hydroxyl groups) and dihydrochlorin Ce6 (0.15 g, 0.25 mmol) were dissolved in 10 ml of anhydrous N, N-dimethylformamide (DMF), and catalysts benzotriazole-1-yl-oxytripyrrolidinophosphine (0.26 g, 0.50 mmol) and N, N-diisopropylethylamine (0.07 g, 0.50 mmol) were added under stirring, and the reaction was carried out at room temperature overnight. After the reaction was completed, the reaction solution was precipitated in excess cold methanol, and the precipitate was collected and dried to obtain hyperbranched polycarbonate hPC-Ce6-AC grafted with photosensitizer Ce6.
[0039] Zwitterions and disulfide compounds were grafted onto hPC-Ce6-AC via a one-pot reaction:
[0040] First, hPC-Ce6-AC was redissolved in DMF, and then, under nitrogen protection, a methanol solution of thiolated zwitterionic carboxybetaine TCB (0.92 g, 2.24 mmol) and triethylamine was added dropwise to the hPC-AC-Ce6 solution, and reacted at room temperature for 12 hours to ensure that TCB was successfully grafted onto hPC-Ce6-AC. The reaction solution was then collected and added dropwise to an excess of 3,6-dioxa-1,8-octanedithiol (0.49 g, 2.69 mmol) to convert the remaining double bonds on the polymer into thiol groups. The reaction was continued at room temperature for 12 hours, and the final reaction solution was dialyzed in methanol to remove unreacted small molecule reactants, and then transferred to ultrapure water for further dialysis to remove the organic solvent. After the dialysis was completed, the solution in the dialysis bag was freeze-dried to obtain the thiolated zwitterionic hyperbranched polycarbonate hPC grafted with photosensitizer Ce6. CB -Ce6-SH.
[0041] High performance liquid chromatography Figure 1 As shown, the results showed that hPC CB The peak time of -Ce6-SH is 2.3 min, which is significantly different from the peak time of free Ce6 6.6 min, indicating that the photosensitizer Ce6 is successfully grafted onto the polymer.
[0042] Example 2
[0043] Preparation and drug loading of ROS-responsive zwitterionic micelles grafted with long-retention photosensitizer Ce6:
[0044] hPC CB 2 mL of PBS (pH 7.4) was added to 10 mg of Ce6-SH and hPC-CB-OBA (10 mg) respectively, and self-assembled under ultrasound. Then, the mixture was mixed and ultrasound was performed in a volume ratio of 1:2. The catalyst triethylamine was added under slow stirring to complete the crosslinking. Then, the mixture was dialyzed in PBS to remove a small amount of triethylamine, and the ROS-responsive zwitterionic micelle RM-Ce6 grafted with photosensitizer Ce6 was obtained.
[0045] like Figure 2 As shown, the dynamic light scattering (DLS) instrument measured the micelle particle size to be 12nm, which is much smaller than the conventional nanocarrier (100-200nm). The multi-mode microplate reader (Molecular Devices spectramax@i3x) showed that the micelles had characteristic peaks of photosensitizer Ce6 at wavelengths of 405nm and 660nm, indicating that the photosensitizer Ce6 was successfully loaded into the micelles. The UV-visible absorption spectrum is shown in Figure 3 .
[0046] The prepared RM-Ce6 was slowly added with stirring to a DMSO solution (50 mg / mL) of sunitinib (St), and then dialyzed with high-purity water to remove unloaded drugs and organic solvents, thereby obtaining the ROS-responsive zwitterionic micelle drug delivery system of the grafted photosensitizer of the present invention, specifically the ROS-responsive zwitterionic micelles of the grafted photosensitizer Ce6 loaded with antivascular drugs (RM-Ce6@St).
[0047] Example 3
[0048] The ability of the grafted photosensitizer Ce6 of the present invention to generate singlet oxygen in response to ROS zwitterionic micelles:
[0049] Singlet oxygen 1 O2 is a type of reactive oxygen species that can be produced through cell metabolism, redox reactions, photosensitization, etc., and can destroy biological cell components such as lipids, proteins, and nucleic acids. 1 O2 detection probe, with 1 O2 binding excites green fluorescence. The laser was irradiated at 660 nm with different powers (0, 100, 150 and 200 mW / cm 2 ) irradiated RM-Ce6 solution containing SOSG (5 μM) and at predetermined time points (20, 40, 60, 80 and 100 s), a multi-mode microplate reader (λ ex =495nm,λ em =535 nm) to measure the fluorescence intensity of the solution.
[0050] The fluorescence intensity of the solution is shown in Figure 4 As shown in A, the fluorescence intensity did not change without light, indicating that there was no 1 O2 production. Under the same power laser irradiation, as the illumination time increases, the fluorescence intensity increases, indicating that RM-Ce6 can continuously produce 1 O2. In addition, Figure 4 As shown in B, with the increase of light intensity, the fluorescence intensity increases faster, indicating that RM-Ce6 produces 1 The above results show that RM-Ce6 has the ability to produce reactive oxygen species under laser irradiation and has the potential to kill tumor cells efficiently.
[0051] Example 4
[0052] Biocompatibility and cytotoxicity of the ROS-responsive zwitterionic micelle drug delivery system of the grafted photosensitizer Ce6 of the present invention under different conditions:
[0053] The MTT method was used to detect the cytotoxicity of micelles grafted with photosensitizers on 4T1 cells. 4T1 cells (7000 cells / well) were seeded in 96-well plates and incubated overnight at 37°C. The cell culture medium was replaced with drug-containing medium containing different concentrations of RM-Ce6 (Ce6: 0.1, 0.6, 1.2, 1.8 and 2.4 μg / mL) and continued to incubate for 12 hours under normoxic or hypoxic conditions. Subsequently, the cells were irradiated with a 660nm laser for 2 minutes or protected from light. After the cells were incubated for another 12 hours, 10 μL of MTT was added to each well. After incubation for 4 hours, the absorbance value (OD) at 490nm was measured using a multi-mode microplate reader to calculate the cell survival rate.
[0054] Cytotoxicity results such as Figure 5 As shown, under dark conditions, the cell survival rate was above 95%, indicating that the micelle RM-Ce6 had good biocompatibility; under normoxic conditions, the cell survival rate of the cells cultured under laser irradiation decreased significantly with the increase of Ce6 concentration, and when the Ce6 concentration was 2.4μg / mL, the cell survival rate was less than 10%; while under hypoxic conditions, the killing ability of RM-Ce6 was significantly reduced, and when the Ce6 concentration was 2.4μg / mL, the cell survival rate was greater than 80%, indicating that the hypoxic microenvironment of the tumor will seriously limit the therapeutic effect of photodynamic therapy, and improving the oxygen supply to the tumor tissue will hopefully improve the photodynamic effect.
[0055] Example 5
[0056] The ROS-responsive zwitterionic micelle drug delivery system grafted with photosensitizer of the present invention promotes vascular normalization and improves hypoxia:
[0057] Female BALB / C mice were subcutaneously injected with 100 μL of 4T1 cell suspension (2.5×10 6 cells / mouse). The tumor grew to 70 mm 3 Tumor-bearing mice were randomly divided into two groups: (1) control (2) RM-Ce6@St. RM-Ce6@St (St dose: 15 mg / kg) was injected into the tail vein on days 0, 2, and 4. 24 hours after the last administration, the O2 content in the tumor tissue was detected by photoacoustic imaging. The tumors were then collected for immunofluorescence detection of the expression level of hypoxia-inducible factor 1α (HIF-1α) in the tumor tissue.
[0058] The photoacoustic signal results are as follows Figure 6 As shown in A in Figure 1, compared with the control group, the oxygenated hemoglobin signal in the tumor tissue increased significantly after anti-angiogenic drug treatment; through quantitative analysis, such as Figure 6As shown in B, the oxygen content in the tumor site increased by 3 times. This result shows that RM-Ce6@St treatment can effectively improve the hypoxia problem of tumor tissue and solve the problem of low efficiency of PDT due to insufficient oxygen content.
[0059] HIF-1α immunofluorescence results Figure 7 As shown in A, after treatment with anti-angiogenic drugs, the fluorescence intensity of HIF-1α in tumor tissues was significantly reduced. Figure 7 B in the figure shows that the positive area of HIF-1α is reduced to below 40%. This indicates that the hypoxia condition in the tumor site has been improved and HIF-1α has been degraded after hypoxia is relieved. The above phenomenon shows that RM-Ce6@St can induce normalization of tumor blood vessels to restore the oxygen transport capacity of tumor blood vessels, thereby effectively alleviating tumor hypoxia, increasing the oxygen content of tumor tissue, and improving the tumor killing effect of PDT.
[0060] Example 6
[0061] The enrichment and retention of the ROS-responsive zwitterionic micelle drug delivery system grafted with photosensitizer of the present invention in tumor-bearing mice:
[0062] When the tumor of the tumor-bearing mice grew to 150mm 3 At 1, 24, 48, 72, 96, 120, and 144 hours after administration, mice were anesthetized with isoflurane and the images were taken using an in vivo imaging system (Perkin Elmer, Fusion FX7 / Lumina TM ) for fluorescence imaging. 144 hours after administration, the tumor-bearing mice were anesthetized and killed, and the heart, liver, spleen, lung, kidney and tumor were collected and subjected to organ stereoscopic imaging.
[0063] In vivo fluorescence imaging results Figure 8 Figure A shows that 24 hours after the ROS-responsive zwitterionic micelle RM was injected into the tail vein, the micelles were clearly enriched in the tumor site, indicating that RM has a high tumor enrichment ability. As time changes, the fluorescence intensity did not show a significant decrease until 144 hours, indicating that RM can stay in the tumor tissue for 6 days and has a long tumor retention ability. The results of in vitro fluorescence imaging are shown in Figure 1. Figure 8 As shown in Figure B, RM is mainly concentrated in the tumor site and less distributed in other organs, indicating that RM has a tumor-specific targeting effect.
[0064] Example 7
[0065] The ROS-responsive zwitterionic micelle drug delivery system of the present invention grafted with photosensitizer mediates tumor vascular normalization and photodynamic therapy in 4T1 tumor-bearing mice:
[0066] Tumor-bearing mice were randomly divided into 4 groups: (I) PBS; (II) RM-Ce6@St; (III) RM-Ce6+L; (IV) RM-Ce6@St+L. Drugs were administered intravenously on days 0, 2, and 4 (St dose: 15 mg / kg, Ce6 dose: 5 mg / kg). On day 5, tumors in groups III and IV were irradiated with 660 nm laser for 15 min. To detect ROS production at the tumor site, one mouse in each group was injected intratumorally with DCFH-DA (100 μM) before laser irradiation, and tumors were collected for frozen sections after laser irradiation. On day 14 of treatment, mice were processed, tumors were collected, photographed, and weighed.
[0067] Tumor treatment results Fig. 9 As shown in A and B in Figure 1, vascular normalization therapy (RM-Ce6@St) and photodynamic therapy (RM-Ce6+L) alone can only slightly inhibit tumor growth. In contrast, long-retention zwitterionic micelles (RM-Ce6@St+L) mediated tumor vascular normalization and photodynamic therapy combined therapy, which significantly inhibited tumor growth, and the tumor of one mouse completely disappeared. Correspondingly, as Fig. 9 As can be seen in C, a large amount of ROS fluorescence signals can be observed in the tumor tissues of the vascular normalization and photodynamic combined treatment groups.
[0068] The above results show that vascular normalization therapy can improve tumor oxygen supply, relieve tumor hypoxia, and remove the limitation of insufficient oxygen in photodynamic therapy. Long-retention micelles are used to co-deliver anti-vascular drugs and photosensitizers. Multiple administrations can achieve the process of vascular normalization while helping photosensitizers to stay in the tumor site for a long time and complete effective accumulation. During the vascular normalization window period, sufficient oxygen supply and a large amount of accumulated photosensitizers produce high concentrations of ROS under laser irradiation to effectively kill tumors. Therefore, the combined treatment advantages of vascular normalization and PDT can be fully utilized through the zwitterionic micelles of the present invention.
Claims
1. A ROS-responsive small-size zwitterionic micelle drug delivery system grafted with a photosensitizer, characterized in that: The drug delivery system is a drug delivery system in which a photosensitizer and an acrylate functional hyperbranched polycarbonate undergo an esterification reaction to obtain a hyperbranched polycarbonate grafted with a photosensitizer, and then the hyperbranched polycarbonate is subjected to Michael addition with a thiolated zwitterionic carboxylic acid betaine and a dithiol compound to obtain a thiolated zwitterionic hyperbranched polycarbonate grafted with a photosensitizer; the thiolated zwitterionic hyperbranched polycarbonate grafted with a photosensitizer and a ROS-responsive hyperbranched zwitterionic polycarbonate are self-assembled and cross-linked in an aqueous solution to obtain ROS-responsive zwitterionic micelles grafted with a photosensitizer, and the micelles are loaded with an anti-angiogenic drug.
2. The zwitterionic micelle drug delivery system according to claim 1, characterized in that: The structure of the acrylate functional hyperbranched polycarbonate is shown in general formula (I), and the structure of the ROS responsive hyperbranched zwitterionic polycarbonate is shown in general formula (II), wherein R1 is selected from H or CH3, and R2 is selected from C2-C4 alkyl or C4-C8 aryl:
3. The zwitterionic micelle drug delivery system according to claim 1, characterized in that: The photosensitizer has a carboxyl functional group, and the anti-angiogenesis drug is a tyrosine kinase inhibitor of the tinib class.
4. The zwitterionic micelle drug delivery system according to claim 1, characterized in that: The disulfide compound is selected from the compounds shown in the following structure: Among them, n=1-50.
5. The zwitterionic micelle drug delivery system according to claim 1, characterized in that: In the drug delivery system, the size of the carrier is 5-20 nm.
6. A method for preparing the zwitterionic micelle drug delivery system according to claim 1, characterized in that: The following steps are involved: (1) esterifying a photosensitizer and an acrylate functional hyperbranched polycarbonate to obtain a hyperbranched polycarbonate grafted with a photosensitizer, and then sequentially reacting the photosensitizer with a thiolated zwitterionic carboxylic acid betaine and a dithiol compound through Michael addition to obtain a thiolated zwitterionic hyperbranched polycarbonate grafted with a photosensitizer; (2) self-assembling the thiolated zwitterionic hyperbranched polycarbonate grafted with the photosensitizer and the ROS-responsive hyperbranched zwitterionic polycarbonate in an aqueous solution, adding a catalyst triethylamine, and stirring to crosslink to obtain ROS-responsive zwitterionic micelles grafted with the photosensitizer; (3) Loading the ROS-responsive zwitterionic micelles grafted with photosensitizer with anti-angiogenic drugs to obtain the ROS-responsive zwitterionic micelle drug delivery system grafted with photosensitizer.
7. The method according to claim 6, characterized in that: In step (1), the molar ratio of the photosensitizer, the acrylate functional hyperbranched polycarbonate, the thiolated zwitterionic carboxylic acid betaine and the dithiol compound is 0.1:1:0.4-0.6:0.1-0.2; the reaction formula for the synthesis of the thiolated zwitterionic hyperbranched polycarbonate grafted with the photosensitizer is:
8. The method according to claim 6, characterized in that: In step (2), the molar ratio of the thiol-modified zwitterionic hyperbranched polycarbonate grafted with the photosensitizer to the ROS-responsive hyperbranched zwitterionic polycarbonate is 1:
1.
9. The method according to claim 6, characterized in that: In step (3), the mass ratio of the ROS-responsive zwitterionic micelles grafted with a photosensitizer to the anti-angiogenic drug is 1:0.1-0.
2.
10. Use of the ROS-responsive zwitterionic micelle drug delivery system grafted with a photosensitizer according to claim 1 in the preparation of drugs for combined vascular normalization and photodynamic therapy.
